Free shipping on all orders over $ 500

URMC-099

Cat. No. M9350

All AbMole products are for research use only, cannot be used for human consumption.

URMC-099 Structure
Size Price Availability Quantity
5mg USD 70  USD70 In stock
10mg USD 105  USD105 In stock
50mg USD 280  USD280 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

URMC-099 is an orally bioavailable, potent mixed lineage kinase type 3 (MLK3) inhibitor with IC50 of 14 nM, which has excellent blood-brain barrier penetration properties. The effect of URMC-099 (URMC099) on tumor formation in vivo is analyzed using a well characterized mouse xenograft model of breast cancer brain metastasis. For these experiments, eGFP8.4 cells are inoculated into the left ventricle of immunodeficient nu/nu mice; animals are then treated with either URMC-099 (10 mg/kg) or vehicle alone, every 12 hours for 20 days. This dose of URMC-099 is chosen because it has been shown to be sufficient to effectively inhibit MLK3 in mice, with good penetration of the blood-brain barrier and potent inhibition of the phosphorylation of Jun N-terminal kinase (JNK) in brain tissue. On day 21 the mice are sacrificed and number of BM is assessed. Fifteen mice are used for each treatment group. BM are detected in 60% of mice, which is consistent with previous studies using this xenograft model by other investigators. URMC-099 treatment significantly (p<0.05, two-tailed t-test) increases the total number of brain metastasis (BM) in mice.

Chemical Information
Molecular Weight 421.54
Formula C27H27N5
CAS Number 1229582-33-5
Solubility (25°C) DMSO ≥ 25 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Rhoo KH, et al. PLoS One. Pharmacologic inhibition of MLK3 kinase activity blocks the in vitro migratory capacity of breast cancer cells but has no effect on breast cancer brain metastasis in a mouse xenograft model.

Related Products
GAPDH-IN-1

GAPDH-IN-1 (GAPDH Inhibitor Compound F8) is a covalent inhibitor of GAPDH (IC50 = 39.31 µM). It viability of, and glucose metabolism in, HEK293 cells in a concentration-dependent manner.

O-acetylcamptothecin

O-acetylcamptothecin is a derivative of camptothecin, a naturally occurring alkaloid extracted from the bark of the Chinese tree Camptotheca acuminata. Camptothecin and its derivatives are primarily known for their potent anticancer properties, particularly through their action as inhibitors of topoisomerase I, an enzyme critical for DNA replication and transcription.

10-hydroxystearic acid

10-hydroxystearic acid is a hydroxy fatty acid.

SB-T-1214

SB-T-1214 is a new-generation taxoid. SB-T-1214 possesses significant activity against colon cancer spheroids induced by and enriched with drug resistant tumorigenic CD133high/CD44high cells and efficiently inhibited expression of the majority of stem cell-related genes.

NG-497

NG-497 is a selective human adipose triglyceride lipase (ATGL) inhibitor that targets the enzymatically active patatin-like domain of human ATGL.

  Catalog
Abmole Inhibitor Catalog




Keywords: URMC-099 supplier, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.